SCHEMBL29379207

SCHEMBL29379207

C/C=C(\C)C(=O)O[C@H]1O[C@H](CO)[C@@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](OC(=O)/C(C)=C/C)[C@H]2O)[C@H](O)[C@H]1O

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ LGALS8 O00214 7/20 0.45
▸ LGALS3 P17931 3/20 0.42
▸ LGALS4 P56470 2/20 0.42
▸ ENGASE Q8NFI3 1/20 0.41
▸ AMY1A P0DUB6 1/20 0.40
▸ LGALS9 O00182 1/20 0.39
▸ LGALS1 P09382 1/20 0.39
▸ LGALS7; LGALS7B P47929 1/20 0.39
▸ FGF1 P05230 2/20 0.39
▸ FGF2 P09038 1/20 0.39
▸ VEGFA P15692 1/20 0.39
▸ HPSE Q9Y251 1/20 0.39
▸ IGF2R P11717 1/20 0.38
▸ AMY2A P04746 1/20 0.38
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29378663 0.90 LGALS8 (0.51) LGALS8LGALS3LGALS4LGALS9LGALS1
SCHEMBL19499655 0.90 LGALS8 (0.51) LGALS8LGALS3LGALS4LGALS9LGALS1
SCHEMBL24495028 0.88 LGALS8 (0.48) LGALS8LGALS3LGALS4FGF1FGF2
SCHEMBL19499656 0.87 LGALS8 (0.47) LGALS8LGALS3LGALS9LGALS1LGALS7; LGALS7B
SCHEMBL29375702 0.87 LGALS8 (0.47) LGALS8LGALS3LGALS9LGALS1LGALS7; LGALS7B
SCHEMBL29376308 0.87 AMY1A (0.39) LGALS8LGALS3LGALS4AMY1ALGALS9
SCHEMBL19499653 0.87 AMY1A (0.39) LGALS8LGALS3LGALS4AMY1ALGALS9
SCHEMBL24495271 0.86 LGALS8 (0.48) LGALS8LGALS3LGALS4LGALS9LGALS1
SCHEMBL24495058 0.82 LGALS8 (0.45) LGALS8LGALS3LGALS4LGALS9LGALS1
SCHEMBL24494995 0.81 LGALS8 (0.44) LGALS8LGALS3LGALS9LGALS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113631562-B Novel compounds and uses thereof 长濑产业株式会社 2024-04-19 — — CN claimed
US-20250333432-A1 NOVEL COMPOUND AND USE OF SAME NAGASE & CO LTD (JP) 2025-10-30 — — US disclosed
CN-120019137-A Cleaning agent composition for animals and method for cleaning animals 动物医院京都株式会社 2025-05-16 — — CN disclosed
JP-2024083004-A EXTERNAL COMPOSITION FOR SKIN 長瀬産業株式会社 2024-06-20 — — JP disclosed
CN-113631562-B Novel compounds and uses thereof 长濑产业株式会社 2024-04-19 — — CN disclosed
US-20220177507-A1 NOVEL COMPOUND AND USE OF SAME NAGASE & CO., LTD. (JP) 2022-06-09 — — US disclosed
EP-3950697-A1 NOVEL COMPOUND AND USE OF SAME Nagase & Co., Ltd. (JP) 2022-02-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220177507-A1 NOVEL COMPOUND AND USE OF SAME TXNRD2, GPX4, GPX1 LGALS8 3562/4885LGALS3 3592/4885LGALS4 2417/4885
US-20250333432-A1 NOVEL COMPOUND AND USE OF SAME TXNRD2, GPX4, GPX1 LGALS8 3562/4885LGALS3 3592/4885LGALS4 2417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback